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Abstract
Supportive care is an essential component of anti-cancer treatment regardless of age or treatment 
intent. As the number of older adults with cancer increases, and supportive care strategies enable 
more patients to undergo treatment, greater numbers of older patients will become cancer 
survivors. These patients may have lingering adverse effects from treatment and will need 
continued supportive care interventions. Older adults with cancer benefit from geriatric assessment 
(GA)-guided supportive care interventions. This can occur at any stage across the cancer treatment 
continuum. As a GA commonly uncovers issues potentially unrelated to anti-cancer treatment, it 
could be argued that the assessment is essentially a supportive care strategy. Key aspects of a GA 
include identification of comorbidities, assessing for polypharmacy, screening for cognitive 
impairment and delirium, assessing functional status, and screening for psychosocial issues. 
Treatment-related issues of particular importance in older adults include recognition of increased 
bone marrow toxicity, management of nausea and vomiting, identification of anemia, and 
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prevention of neurotoxicity. The role of physical therapy and cancer rehabilitation as a supportive 
care strategy in older adults is important regardless of treatment stage or intent.
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Introduction—What Is Supportive Care?
The National Cancer Institute define supportive care as follows:
Care given to improve the quality of life of patients who have a serious or life-
threatening disease. The goal of supportive care is to prevent or treat as early as 
possible the symptoms of a disease, side effects caused by treatment of a disease, 
and psychological, social, and spiritual problems related to a disease or its 
treatment. Also called comfort care, palliative care, and symptom management [1].
The Multinational Association for Supportive Care in Cancer (MASCC) uses a slightly 
different definition that potentially goes beyond just the cancer and its treatment.
Supportive care in cancer is the prevention and management of the adverse effects 
of cancer and its treatment. This includes management of physical and 
psychological symptoms and side effects across the continuum of the cancer 
experience from diagnosis through treatment to post-treatment care. Supportive 
care aims to improve the quality of rehabilitation, secondary cancer prevention, 
survivor-ship, and end-of-life care [2].
Supportive Care and Survivorship in the Older Adult with Cancer
Cancer and cancer treatment may result in long-term and late effects that can have a major 
impact on patient quality of life [3, 4]. Cancer survivorship and supportive care initiatives 
point us to the importance of the physical, functional, and psychosocial needs for patients 
and their caregivers from the time of the cancer diagnosis for the remainder of their life [5]. 
This definition of survivorship has been acknowledged by leading authorities [6] and 
stresses the importance of supportive care throughout the continuum of the patients’ illness.
Survivorship care is particularly important for older cancer survivors who may have baseline 
vulnerability or frailty. This decrement in functional status potentially heightens the 
possibility of experiencing cancer and treatment-related toxicity that can further increase the 
risk for lasting adverse effects. It is especially important for the older person that clinicians 
take into account the patient’s physiological reserve starting at the time of diagnosis and 
continuing through treatment decision-making, planning, and surveillance. In addition, older 
cancer patients are to be closely monitored for the development of signs and symptoms of 
toxicity, allowing for early intervention such as modification of cancer therapy and/or 
institution of supportive care. The opportunities to intervene with supportive care strategies 
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occur at all time points along the cancer journey. This review provides a comprehensive 
outline and practical guidance for age-appropriate survivorship and supportive care.
Geriatric Assessment As a Supportive Care Strategy
Multiple chronic health conditions, functional disabilities, and geriatric syndromes impact 
prognosis and treatment outcomes in older patients with cancer [7]. Older patients are more 
vulnerable to treatment side effects [8]. Treatment toxicity can worsen underlying chronic 
health conditions and may potentiate functional dependence and geriatric syndromes such as 
depression, dementia, falls, and malnutrition [8]. Supportive care management of older 
patients with cancer requires an approach that systematically assesses health status, 
functional abilities, and evaluation of geriatric issues unique to the individual.
Geriatric assessment (GA) is a multidimensional assessment of an older patient’s health, 
functional status, and geriatric syndromes. A GA-guided supportive care process can be used 
as a strategy to identify evidence-based interventions for specific issues that may interfere 
with treatment and impact quality of survival [9•]. GA is comprised of validated tools to 
assess areas of health referred to as domains [7]. Potential domains include the following: 
(1) medical: evaluation of co-morbidity, polypharmacy, and nutritional status; (2) mental 
health: evaluation of cognition, depression, and delirium; (3) functional status: assessment of 
activities of daily living (ADL) [10]; instrumental activities of daily living (IADL) [11]; 
physical performance (mobility); and falls and (4) social: evaluation of environment, 
resources, and social support [12].
Implications of the Findings of a Geriatric Assessment for Supportive Care
The findings from a comprehensive geriatric assessment can be used to guide supportive 
care interventions and an individualized supportive care management plan [9•]. Key domains 
in this assessment include the following:
Comorbidity
Comorbidity increases with age [13]. Care management decisions must include a careful 
consideration of the likely impact of chronic conditions on cancer and cancer treatment as 
well as the possible effect of treatment on underlying comorbidity. For example, increased 
incidence of treatment-related cardiomyopathy is associated with older age, baseline 
cardiomyopathy, and history of hypertension in patients treated with anthracyclines and 
trastuzumab [14]. Patients with existing neuropathy may be at increased risk from falls when 
given neurotoxic chemotherapy [15]. Baseline renal function must be assessed in older 
adults prior to commencing potentially nephrotoxic or renally excreted drug therapy [16]. In 
addition to a simple assessment of the number, type, and severity of comorbidities, the 
Charlson Comorbidity Index [17] and the Cumulative Illness Rating Scale for Geriatrics [18] 
are validated tools to characterize comorbidity burden.
Polypharmacy
In addition to having a high comorbidity burden, older adults with cancer are likely to see 
multiple specialists and receive multiple additional medications for symptoms related to 
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cancer and its treatment [19, 20]. A high-quality GA should therefore include a full 
medication reconciliation and individualized evaluation of appropriateness of a patient’s 
entire medication regimen; both prescription and non-prescription including supplements 
and complementary and alternative medicines (CAM). Complementary and alternative 
medicine use is a potential source of polypharmacy and drug-drug interactions [21]. 
Moreover, several cross-sectional studies in geriatric oncology have demonstrated that older 
patients with cancer are routinely exposed to polypharmacy, or excess medication use, and 
unnecessary and inappropriate medications, defined as medications with a high risk to 
benefit ratio [19, 22, 23••, 24, 25]. Several tools can be used to identify medications that are 
considered inappropriate in older adults; the most widely used being the Screening Tool for 
Older Peoples’ Prescriptions (STOPP) and the American Geriatrics Society Beers Criteria 
[26, 27]. In addition, for patients who have advanced disease or a limited life expectancy, 
tools exist that incorporate frailty, functional status, life expectancy, and goals of care into 
treatment decisions around discontinuing medications [28–30]. Addressing polypharmacy is 
an important part of a multidisciplinary supportive care strategy in older adults with cancer.
Nutrition
Malnutrition is associated with poor outcomes in older adults [31] and can have multiple 
unintended consequences. Chemotherapy-induced nausea/vomiting, anemia, and fatigue can 
potentiate poor nutrition, and likewise, poor nutrition can worsen fatigue. The Mini 
Nutritional Assessment (MNA) [32] is a six-item questionnaire that can be used to identify 
patients at risk for malnutrition. Interventions for patients at risk of malnourishment include 
the following: (1) referral to dietician for nutritional assessment and advice; (2) assessment 
for depression, access to food, and social support; and (3) implementation of community 
services such as home-delivered meals and support for meal preparation and shopping [33].
Cognition/Delirium
Patients with preexisting cognitive impairment are at particular risk of complications such as 
delirium during cancer treatment. It is important to identify cognitive impairment as part of a 
GA-guided supportive care management plan [9]. The Mini Mental Status Exam (MMSE) 
[34] and Montreal Cognitive Assessment (MoCA) [35] are available screening tools for 
cognitive impairment. Patients with cognitive impairment require further evaluation for 
reversible causes, capacity evaluation, assessment of ADL and IADL, and support for 
monitoring of toxicity (i.e., home health care). Older patients with cancer are at risk for 
delirium due to polypharmacy, anemia, dehydration, and electrolyte disturbances. 
Assessment for delirium is important with acute changes in mental status. Delirium can be 
diagnosed with high sensitivity and specificity with the Confusion Assessment Method [36].
Depression
Depression is often undertreated and underrecognized in older adults [8]. Anhedonia can 
impede the ability to adhere to treatment. Late life depression can be effectively treated with 
antidepressants or psychotherapy [37]. Treatment with pharmacotherapy can be complex and 
referral to psychiatry is warranted as few older adults receive adequate treatment [38]. 
Structured psychosocial interventions that include behavioral activation and problem-solving 
have been shown to be effective management in older adults with cancer [39]. Validated 
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questionnaires for depression include the Hospital Anxiety and Depression Scale (HADS) 
[40], the Center for Epidemiologic Studies on Depression (CESD-20) [41], the Beck 
Depression Inventory (BDI) [42], and the Geriatric Depression Scale (GDS) [43]. Clinicians 
caring for older adults with cancer can initiate pharmacotherapy, assess for risk factors for 
suicide, evaluate for underlying conditions that can contribute to depression such as anemia 
and thyroid disorders, review medications, and assess for psychosocial factors (ensure 
adequate social support, caregiver stress, financial burden) that can contribute to depressive 
symptoms [8].
Functional Status, Mobility, and Falls
Functional impairment is common in older patients with cancer [44]. Functional status 
includes the ability to complete tasks of basic self-maintenance (ADL) and skills necessary 
to live independently in the community (IADL). These tasks are evaluated by the Katz ADL 
Index [10] and Lawton IADL scale [11]. Depression and impairment in IADL predict 
functional decline following the first cycle of chemotherapy [45]. Longer hospitalization, 
fatigue, and IADL dependence are found in older patients with functional impairment prior 
to cancer surgery [46]. Referral to physical and occupational therapy and assessment of 
social support and cognition are important next steps in the evaluation of functional 
impairment.
Mobility and fall risks are assessed by physical performance tests. Older patients with cancer 
are particularly at risk for falls secondary to treatment side effects and advanced stage [47]. 
Patients with history of falls within the last 6 months should be assessed for gait impairment, 
balance, and vitamin D level. The Timed Up and Go (TUG) [48] and Short Physical 
Performance Battery (SPPB) [49] are physical performance assessments for gait, strength, 
and balance. Early interventions for patients with a history of falls include the following: (1) 
medication review, (2) addressing vision impairment, (3) physical therapy and exercise 
programs with goals to strengthen muscles and improve balance, (4) Vitamin D repletion, 
and (5) home safety evaluation and implementation of emergency response system for 
patients who live alone [50].
Social
Assessment of social supports including presence of a caregiver, financial status, and 
availability of transport is a key component of a GA-based supportive care strategy [9]. A 
basic question to ask the patient is “who is available to help in case of an emergency?” 
Informal care-givers can provide support to older cancer patients to compensate for the 
impact of functional and cognitive decline. They also provide emotional and social support 
which is essential to the well-being and quality of life of cancer patients [51]. A social 
worker in a supportive care team can help review resources and available supports. The older 
patient with cancer may also be a caregiver for others; thus, particular attention is needed to 
the whole social situation.
Prediction of Toxicity
GA domains can be predictive of chemotherapy toxicity. The Cancer and Aging Research 
Group (CARG) developed a risk model that includes geriatric factors predictive of grades 3–
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5 chemotherapy toxicity. Impairment in IADL, mobility, hearing, falls, and decrease in 
social activities predicted grades 3–5 chemotherapy toxicity [52]. The Chemotherapy Risk 
Assessment Scale for High-Age Patients (CRASH) model predicts severe hematologic and 
non-hematologic toxicity. In this model, impairment in IADL predicted hematologic 
toxicity; malnutrition and abnormal cognition predicted non-hematologic toxicity [53]. 
Similarly, nutrition, impaired function, and comorbidity predicted interruption of 
chemotherapy in older patients with solid malignancies receiving chemotherapy [54]. Thus, 
geriatric assessment at diagnosis and at the initiation of treatment can be used to identify 
patients with higher risks of toxicity and to guide treatment modifications and supportive 
care interventions to avoid this toxicity.
Supportive Care for Treatment-Related Issues
Older patients may be at risk of certain treatment-related toxicities. Supportive care 
strategies are particularly important in the following areas:
Bone Marrow Toxicity
(a) Neutropenia and infection—It is generally accepted that the risk of hematological 
toxicity is increased in older adults (≥65 years) undergoing myelosuppressive chemotherapy. 
Older adults are at risk of febrile neutropenia (FN) and life-threatening infections that may 
in turn lead to reduced dose intensity and decreased effectiveness of treatment. Prophylaxis 
with granulocyte colony-stimulating factors (G-CSFs) serves to reduce the rate of 
neutropenic infection and improve dose intensity [55].
Clinical guidelines from the American Society of Clinical Oncology (ASCO) [56], the 
National Comprehensive Cancer Network (NCCN) [57], and the European Society of 
Medical Oncology (ESMO) [58] recommend that primary G-CSF prophylaxis be given to all 
patients over the age of 65 if they are receiving chemotherapy which confers a >20 % risk of 
febrile neutropenia. The 2010 update of the EORTC guidelines for CSF use include a 
detailed analysis of factors in addition to age which may further increase risk of FN [59]. 
The use of growth factors may be indicated in older adults with these comorbidities even if 
the FN risk of a particular chemotherapy regimen is cited as between 10 and 20 %.
This use of prophylactic growth factors is particularly relevant to older patients receiving 
anthracycline-based regimens as curative treatment for non-Hodgkin’s lymphoma [60]. A 
recent analysis of 5884 patients over age 65 using SEER data found that clinicians’ 
adherence to guidelines recommending primary G-CSF prophylaxis in elderly patients with 
NHL receiving anthracycline-based chemotherapy now approaches 70 % in the USA [61•]. 
Primary prophylaxis reduced the risk of outpatient encounters for fever or infection but did 
not have an impact on inpatient encounters or deaths during cycle 1 of chemotherapy.
The MASCC febrile neutropenia risk score can be used to potentially identify patients with 
established FN who may be at increased risk of complications [62, 63]. It has been used to 
identify “low risk” patients who could be managed as outpatients. This index uses age over 
60 years as a risk factor for FN complications (Table 1) [62].
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(b) Anemia—The assessment of anemia is an important part of any supportive care 
strategy in older adults with cancer as the incidence and prevalence of anemia increases with 
age. Screening for anemia and the investigation of possible causes is recommended as part 
of pretreatment assessment. Anemia is a risk factor for chemotherapy-related toxicity and 
has been associated with functional dependence, falls, cardiac failure, cognitive impairment, 
and dementia [12].
Causes of anemia in the older adult are often multifactorial [64], but correction of reversible 
causes such as iron deficiency should be pursued and addressed as a matter of urgency. The 
NCCN guidelines for management of cancer and chemotherapy-induced anemia include 
management algorithms that apply to patients regardless of age [65].
Once the cause of anemia has been ascertained, a number of treatment strategies are 
available. The new formulations of IV iron are associated with fewer side effects and better 
efficacy than oral iron. There is a suggestion that IV iron may reduce the need for 
transfusions in some settings [66].
The utility of erythropoietin-stimulating agents (ESAs) in patients with cancer remains 
contentious and is generally not recommended due to the increased risk of adverse events 
such as thrombosis and the evidence of possible decreased survival in patients receiving 
these agents.
Judicious use of red blood cell transfusions remains the mainstay of treatment of 
symptomatic anemia in older patients with cancer. Transfusions are not generally 
recommended for asymptomatic patients unless the hemoglobin level is between 7 and 8 
g/dL [65].
Treatment-Induced Nausea and Vomiting—Antiemetics
Although chemotherapy-induced nausea and vomiting (CINV) is less common in older 
adults [67], the risk of adverse consequences such as dehydration and renal impairment is 
higher due to the increased likelihood of comorbidities. Supportive care guidelines for the 
prevention of CINV are applicable to patients of all ages [68, 69], and with modern therapy, 
vomiting can be completely prevented in 70–89 % of cases [70, 71]. Antiemetic therapy is 
highly effective in older adults but care needs to be taken in specific circumstances. The 
potential for drug-drug interactions with some agents is a theoretical problem that rarely 
arises in practice. More of a concern is the increased likelihood of unstable diabetes and 
insomnia with the use of corticosteroids and the increased risk of constipation with 5HT3 
antagonists [72]. Careful counseling on the use of laxatives around the time of chemotherapy 
is an important supportive care strategy.
Treatment-Induced Neurotoxicity and Falls
The evidence for an increased incidence of neurotoxicity in older adults is conflicting and 
dependent upon the chemotherapy drug in question [73]. While there is no evidence that 
older patients are at increased risk from platinum-agents such as oxaliplatin, there is some 
evidence of an increased risk of clinically significant peripheral neuropathy due to paclitaxel 
in older women with ovarian cancer [74, 75]. There are currently no recommendations for 
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dose modification of taxanes in older patients, but caution needs to be exercised in patients 
with preexisting neuropathy.
A recent systematic review of falls in patients with cancer identified 31 studies exploring 
this topic [76]. The authors reported that falls are more common in older patients with 
cancer than in community-dwelling older adults without cancer. A number of factors 
increasing the risk of falls included pain and chemotherapy type. The risk of falls increased 
with the administration of doublet vs single-agent neurotoxic chemotherapy and with 
increasing number of cycles of these agents [47, 77]. Other established risk factors for falls 
in the general population such as prior history of falls and dependence in ADLs are also risk 
factors in older adults with cancer [76].
Cancer Rehabilitation for the Older Adult
Physical supportive care strategies are important in older adults regardless of the timing and 
intent of anticancer treatment. Older adults who have cancer are at a higher risk of reporting 
that they are in poor or fair health, higher levels of disability, increased number of falls, and 
higher levels of functional decline [78–81]. The ultimate goal of cancer rehabilitation is to 
improve the quality of life of people with cancer and can be provided at any age and stage of 
cancer continuum [82]. The cancer rehabilitation team usually consists of occupational and 
physical therapists who work together and in parallel with other supportive care services. 
Occupational and physical therapists strive to improve function, decrease disability, decrease 
risk of falling, and improve quality of life, yet referral to cancer rehabilitation has been 
underutilized [83, 84•]. Improving access to these services can occur through detection of 
need via a GA or even a simple question about previous falls [85].
Occupational therapy assists people across the lifespan to engage in activities to improve 
quality of life [86]. Occupational therapists use meaningful activity therapeutically to restore 
abilities or, through an adaptive model, modify the environment or the activity to allow for 
participation [86]. For older adults with cancer, participation in ADL and IADL is vital to 
improved survival and quality of life [87]. Examples of interventions occupational therapists 
may provide include the following: self-care management, environmental adaptation, 
cognitive rehabilitation, fall risk prevention, medication management, upper extremity 
mobility and exercise, lymph-edema care, and management of peripheral neuropathy and of 
cancer-related fatigue [88, 89].
Exercise can improve overall quality of life [90, 91]. Physical therapy can provide 
individualized exercise programs to those with a variety of comorbid conditions, physical 
limitations, or gait and balance disturbances [92]. Physical therapists individualize exercise 
and mobility treatment plans in order to maintain function and slow down or prevent future 
disability. Through increasing exercise and physical mobility, physical therapy can also 
decrease pain and improve balance to decrease fall risk [93–96].
Both physical and occupational therapy can be provided at any stage of the cancer care 
continuum including pretreatment. Pretreatment can include exercise and endurance training 
prior to surgery [97] to provide education about the potential impact of treatment, how to 
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preserve ability to complete daily activities, and the importance of physical activity and 
mobility after surgery. Furthermore, prehabilitation can provide patients with education on 
how to maintain range of motion and provide specific exercises and fittings for adaptive 
devices as needed [82, 98].
Supportive Care in the Older Adult with Cancer at the End of Life
In patients of any age with advanced illness end of life supportive care is critical in 
addressing untreated symptoms that diminish function and quality of life. Symptoms such as 
pain, fatigue, functional dependence, and delirium are not unique to older patients, but can 
be more prevalent and challenging to treat in this population [99]. A Swedish study 
identified older age as a risk factor for poor end-of-life quality in cancer patients because 
younger patients were routinely informed more often about imminent death, more 
systematically assessed for pain and other symptoms, and more likely to be assessed by a 
formal palliative care service. In addition, the families of younger patients were more likely 
to be informed about imminent death and to be offered support in bereavement [100]. As is 
the case earlier in the disease trajectory, supportive care strategies need to be individualized 
to the patient’s physiologic and social reserve. Certain medications may be higher risk in 
older patients due to physiologic changes, altered pharmacokinetics, comorbidity burden, 
and polypharmacy. While non-pharmacological approaches are thus very important, it 
should be acknowledged that older patients are also at risk of undertreatment of symptoms 
due to fear of toxicity. Optimal treatment requires a more cautious approach to initiation and 
titration, with a commitment to continuing to increase medication use as appropriate to 
alleviate symptoms. Adequate supportive care at the end of life must also focus on the 
caregivers [99, 101]. Family and carers are often unaware of the changes that occur at the 
very end of life and education can serve to alleviate panic and distress [99]. Although 
prediction of death itself is not possible, providers can educate family members about the 
signs and symptoms of the terminal phases of death. Helping caregivers to anticipate this can 
help to lessen the anxiety and stress of the approach of death [102]. Delirium can be present 
during the dying process and is more likely to happen if the patient has experienced delirium 
prior to the end of life. It is key to educate families about the potential causes of and 
interventions for terminal delirium [103]. When patients experience terminal delirium, a 
shift toward providing comfort through use of sedatives may be appropriate, even if patients 
become less alert as a result [104]. Elderly patients may present differently in these stages, 
and close monitoring of symptoms is imperative to ensure the greatest reduction of patient 
suffering.
Conclusion
Care of the older adult with cancer relies upon adequate assessment as a guide for 
appropriate treatment. A multidimensional geriatric assessment with guided intervention is a 
vital part of this strategy. As many of the issues uncovered by a GA are unrelated to 
treatment of the cancer, it can be argued that a GA is actually a sophisticated approach to 
providing optimal supportive care. The provision of supportive care is crucial to reduce 
morbidity and enhance wellbeing throughout the survivorship trajectory: from diagnosis to 
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end of life. Multidisciplinary teams including oncologists, geriatricians, nurses, pharmacists, 
social workers, and physical therapists need to work together to achieve this aim.
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Table 1
MASCC febrile neutropenia risk score
Characteristic Weight
Burden of illness: no or mild symptoms 5
No hypotension 5
No chronic obstructive pulmonary disease 4
Solid tumor or no previous fungal infection 4
No dehydration 3
Burden of illness: moderate symptoms 3
Outpatient status 3
Age <60 years 2
A total score of ≥21 identified patients at low risk of complications from febrile neutropenia. Points attributed to the variable “burden of illness” are 
not cumulative. The maximum theoretical score is therefore 26. From Klastersky J., Paesmans M., The Multinational Association for Supportive 
Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 
2013;21(5):1487–95. doi:10.1007/s00520-013-1758-y, with permission of Springer
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